🇺🇸 FDA
Patent

US 12208092

Compositions and methods for administering paltusotine to patients with hepatic impairment

granted A61KA61K31/381A61K31/4709

Quick answer

US patent 12208092 (Compositions and methods for administering paltusotine to patients with hepatic impairment) held by CRINETICS PHARMACEUTICALS, INC. expires Mon Jan 23 2045 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
CRINETICS PHARMACEUTICALS, INC.
Grant date
Tue Jan 28 2025 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Jan 23 2045 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
27
CPC classes
A61K, A61K31/381, A61K31/4709, A61K9/0053, A61K9/2013